There is no comparison to DNA SEQ.
303
-
Genuine DFG INTER drug candidates.
-
Many of these drug candidates have in vitro and in vivo data.
6
-
Cancer indications with previously validated targets.
-
Indications include: lung, breast, melanoma, bladder, gallbladder and leukemia.
-
We are unique in our ability to target a large section of the entire market place as an alternative to ATP competitive inhibitors.
-
A revolutionary AI assisted approach to targeted therapies.
1
-
Proof-of-concept for drug resistant patients with leukemia.
Clinical Trial Partner
-
World class clinical trial partner already engaged who support our ground breaking discoveries.
-
"A unique paradigm for a new platform of oncogenic kinase inhibition" ~ Dr Brian Druker.
World's most credible life sciences team with historic success
Key scientists involved at DNA SEQ were involved in the creation of the ATP competitive kinase inhibitor market place.
​
The same people are now bringing forwards the next revolution in targeted therapies to address drug resistance. This platform form of moleluces are known as DFG INTER kinase inhibitors.
​
DFG INTER binding sites have a number of attributes including allosteric binding site features as opposed to ATP binding site that result in drug resistance.
World class CRO - Start to finish
Collaboration
There are areas that may provide for collaboration with DNA SEQ in our area of specialty. If you would like to discuss working with us on collaborative efforts, we know there are exceptional people and groups that we can create solutions with.
​
We have partnered with Selvita to take our product all the way to completion. Selvita are world class in all aspects of small molecule drug development
Selvita and DNA SEQ share the same vision - to bring the next evolution of cancer fighting drugs to the world and improve lives.
​
